Patents
Literature
8 results about "Uncoupling protein" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
An uncoupling protein (UCP) is a mitochondrial inner membrane protein that is a regulated proton channel or transporter. An uncoupling protein is thus capable of dissipating the proton gradient generated by NADH-powered pumping of protons from the mitochondrial matrix to the mitochondrial intermembrane space. The energy lost in dissipating the proton gradient via UCPs is not used to do biochemical work. Instead, heat is generated. This is what links UCP to thermogenesis. UCPs are positioned in the same membrane as the ATP synthase, which is also a proton channel. The two proteins thus work in parallel with one generating heat and the other generating ATP from ADP and inorganic phosphate, the last step in oxidative phosphorylation. Mitochondria respiration is coupled to ATP synthesis (ADP phosphorylation) but is regulated by UCPs.
Application of isohesperidin in preparation of medicine for preventing and treating obesity or related metabolic syndrome thereof
The invention belongs to the field of biological medicines, and relates to application of isohesperidin or pharmaceutically acceptable salts thereof in preparation of medicines for preventing and / or treating obesity or related metabolic syndromes thereof. The invention finds that the natural compound isohesperidin can obviously induce adipocyte browning and improve the expression level and the cell oxygen consumption rate of uncoupling protein 1, so that the weight gain is effectively inhibited and the glucose homeostasis and the insulin sensitivity are improved in an obesity mouse model, and meanwhile, the isohesperidin can be used for inhibiting the adipocyte browning. No obvious cytotoxicity and animal toxicity are observed in an effective dose of isohesperidin, so that the isohesperidin has better safety and is expected to be used for preventing and / or treating obesity or related metabolic syndromes thereof.
Owner:XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
Application of hippuric acid in activating brown adipose tissue to produce heat and preventing and treating obesity
The invention discloses application of hippuric acid in activation of brown adipose tissue heat production and prevention and treatment of obesity, and the application is realized by activating brown adipose tissue heat production, specifically, expression of uncoupling protein 1 in brown adipose tissue is up-regulated, heat production capacity under cold stimulation conditions is enhanced, weight gain and abnormal glucose and lipid metabolism are improved, and the purpose of preventing and treating obesity is achieved. The hippuric acid is preferably derived from walnut oil or metabolites thereof, and has a good application prospect.
Owner:JIANGNAN UNIV
Khusim-type diterpenoid compound, and preparation method and application thereof
PendingCN122627895AFat mouseEuphorbia acanthothamnos
The present application relates to a kaurane diterpenoid compound D-33 extracted and separated from the roots of Euphorbia griffithii Hook., a preparation method and uses thereof. Bioactivity tests show that the compound D-33 has a significant weight loss effect in a high-fat diet-induced obese mouse model, can effectively activate uncoupling protein 1 (UCP1) in vitro, and can be used for preparing a thermogenic anti-obesity drug.
Owner:INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
Adipose cell, white fat browning cell model, construction method and application
The invention provides an adipocyte, a white adipose browning cell model and a construction method and application, and relates to the technical field of biological medicine, the adipocyte contains an exogenous nucleic acid construct for specifically inhibiting Kdm7a gene expression; expression of the endogenous Kdm7a gene in fat cells is inhibited and an uncoupling protein 1 is expressed. By specifically inhibiting the expression of Kdm7a, the adipocyte can obviously express the uncoupling protein 1 and presents a stable brown adipotype, so that the defects of limited cell source, complex induction and high heterogeneity in the prior art are effectively overcome; a standardized model which is simple and convenient to operate, wide in source and definite in function is provided for metabolic disease mechanism research and drug screening.
Owner:CHONGQING MEDICAL UNIVERSITY
Protein regulating activity of mitochondrial calcium ion channel and application thereof in prevention and treatment of obesity and related diseases
The present application relates to a protein for regulating the activity of a mitochondrial calcium channel and its application in preventing and treating obesity and related diseases, and belongs to the field of adipose tissue and related metabolism. The technical problem to be solved by the present application is how to prevent and / or treat obesity or obesity-related diseases. To solve the above technical problem, the present application provides a protein, which is an EMRE-UCP1 protein, wherein the EMRE-UCP1 protein is a protein fused from a mitochondrial calcium ion transport regulatory protein and a uncoupling protein-1. To solve the above technical problem, the present application provides a method for drug screening, wherein the method comprises using the transgenic animal cell line, or the transgenic animal tissue, or the transgenic animal organ of B11) to perform drug screening, and the drug is a drug for preventing and / or treating obesity or obesity-related diseases.
Owner:PEKING UNIV
VGLL4 with UCP-1 cis-regulatory element and method of use thereof
Provided is a polynucleotide, including a cis-regulatory element and a nucleotide sequence encoding a vestigial like 4 protein, wherein the cis-regulatory element includes an uncoupling protein 1 enhancer and an uncoupling protein 1 promoter. Also provided is a viral vector including said polynucleotide. Also provided is a method of transfecting a cell or a subject with said polynucleotide or said viral vector.
Owner:MASONIC MEDICAL RES LAB A CORP OF NY
Drug combination for treating obesity
ActiveUS12642790B2Metabolism disorderPeptide/protein ingredientsAdrenergic receptor agonistsPharmaceutical Substances
The present invention provides methods of treating obesity, pre-diabetes, diabetes, and / or obese breast cancer, by increasing mitochondrial metabolism by increasing the activity of uncoupling protein 1 (UCP1) in adipocytes. The disclosed methods comprise contacting an adrenergic receptor agonist with an adipocyte in which the genomic activity of estrogen receptor beta (ERβ) has been inhibited or inactivated. In certain aspects, inhibition or inactivation of the genomic activity of ERβ is achieved by contacting the adipocyte with an ERβ ligand that selectively inhibits or inactivates the ERβ genomic activity.
Owner:THE CURATORS OF THE UNIVERSITY OF MISSOURI
Application of kinetin in preparation of medicine for preventing and / or treating obesity, fatty liver and liver injury induced by high fat
The invention belongs to the technical field of medicines, and particularly relates to application of kinetin in preparation of medicines for preventing and / or treating obesity, fatty liver and liver injury induced by high fat. The kinetin has a potential anti-obesity effect. Results of embodiments show that the kinetin can significantly reduce weight gain of mice caused by high fat induction, and after the kinetin is administered, the body type and white fat of the mice are reduced, the glucose tolerance is increased, the insulin sensitivity is increased, and the UCP1 (uncoupling protein 1) level of brown fat of a kinetin administration group is increased, which indicates that the kinetin can play a role in resisting obesity.
Owner:MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI